12月31日，安杰思跌1.08%，截至发稿，报58.59元/股，成交2297.36万元，换手率0.94%，总市值47.53 亿元。 资料显示，杭州安杰思医学科技股份有限公司位于浙江省杭州市临平区兴中路389号，成立日期2010年 12月6日，上市日期2023年5月19日，公司主营业务涉及从事内镜微创诊疗器械的研发、生产与销售。主 营业务收入构成为：GI类62.74%，EMR/ESD类23.26%，ERCP类11.04%，仪器类2.21%，其他0.74%。 从基金十大重仓股角度 数据显示，华泰保兴基金旗下1只基金重仓安杰思。华泰保兴健康消费A（006882）三季度持有股数 3640股，占基金净值比例为6.03%，位居第六大重仓股。根据测算，今日浮亏损失约2329.6元。 华泰保兴健康消费A（006882）成立日期2019年5月27日，最新规模74.14万。今年以来亏损14.34%，同 类排名8076/8085；近一年亏损15.05%，同类排名8073/8085；成立以来亏损10.2%。 华泰保兴健康消费A（006882）基金经理为赵旭照。 截至发稿，赵旭照累计任职时间7年353天，现任基金资产总规模6.53亿元 ...

Core Viewpoint - The company Anjies (688581.SH) announced that its subsidiary Hang'an Medical Technology (Hangzhou) Co., Ltd. has received medical device registration certificates from the Zhejiang Provincial Drug Administration for several endoscopic products, enhancing its product line in the endoscopy field [1] Group 1 - The registered products include an electronic endoscope image processor, an upper gastrointestinal electronic endoscope, and a lower gastrointestinal electronic endoscope [1] - The acquisition of these medical device registration certificates enriches the company's product offerings in the endoscopy diagnosis and treatment sector, addressing diverse clinical needs [1] - This development is expected to improve the company's overall market competitiveness and positively impact its sustainable growth [1]

Core Viewpoint - Anjias (688581.SH) has received medical device registration certificates for its electronic endoscope imaging processor and both upper and lower gastrointestinal electronic endoscopes, indicating a significant advancement in its product offerings in the endoscopy field [1][2]. Group 1: Company Developments - The registration certificates include the endoscope main unit (including imaging processor and light source), upper gastrointestinal electronic endoscope, lower gastrointestinal electronic endoscope, and peripheral equipment, aimed at early cancer diagnosis and treatment [1]. - The acquisition of these medical device registration certificates enhances the company's product line in the endoscopy sector, catering to diverse clinical needs and improving overall market competitiveness [2]. Group 2: Industry Insights - The endoscope and endoscopic treatment consumables market in China is experiencing rapid growth, driven by strong government support and increased R&D investment from domestic manufacturers [1]. - Domestic core products are gradually matching the performance parameters of foreign brands, with some key technologies achieving industry leadership, significantly enhancing market competitiveness and accelerating the process of domestic substitution [1].

证券日报网讯12月24日，安杰思在互动平台回答投资者提问时表示，截至2025年12月20日，公司的股东 人数为6529户。 ...

Core Viewpoint - The company Anjisi (688581.SH) has received medical device registration certificates for its endoscopic products, indicating a significant advancement in its product offerings and competitiveness in the domestic market [1][2]. Group 1: Product Registration - Anjisi's subsidiary Hang'an Medical has obtained medical device registration certificates for three products: electronic endoscope image processor, upper gastrointestinal electronic endoscope, and lower gastrointestinal electronic endoscope [1]. - The registration numbers for these products are: 20252062013 for the image processor, 20252062011 for the upper endoscope, and 20252062012 for the lower endoscope [1]. Group 2: Market Growth and Competitive Position - The endoscope and related diagnostic consumables market in China is experiencing rapid growth, driven by strong government support and increased R&D investment from domestic manufacturers [1]. - Domestic core products are gradually matching the performance parameters of foreign brands, with some key technologies achieving industry leadership, significantly enhancing market competitiveness and accelerating the process of domestic substitution [1]. Group 3: Impact on Company Development - The acquisition of these medical device registration certificates enriches the company's product line in the endoscopy field, meeting diverse clinical needs and enhancing overall market competitiveness [2]. - This development is expected to have a positive impact on the company's sustainable growth [2].

Core Viewpoint - Anjie's subsidiary, Hangzhou Anji Medical Technology Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration, enhancing its product line in the endoscopy field and improving market competitiveness [1] Group 1: Product Registration - The medical device registration certificate is valid from December 23, 2025, to December 22, 2030 [1] - The registered products include electronic endoscope image processors, upper gastrointestinal electronic endoscopes, and lower gastrointestinal electronic endoscopes [1] Group 2: Product Functionality - These products are designed to process signals from electronic endoscopes, provide illumination, and work in conjunction with image processors to display images for observation, diagnosis, and treatment of the upper and lower gastrointestinal tracts [1] Group 3: Market Impact - The acquisition of the registration certificate enriches the company's product line in the endoscopy sector, which is expected to enhance its overall competitiveness in the market [1]

证券代码：688581 证券简称：安杰思 公告编号：2025-068 | 序 | 产品名称 | 证书编号 | 注册证有效期 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 号 | | | | | | | | | | | | 察、诊断和治疗用。 | 二、对公司的影响 目前，我国窥镜设备及内镜下诊疗耗材市场保持高速增长态势，在国家政策 大力扶持与国产厂商持续加大研发投入的双重驱动下，国内自主研发的核心产品 在整体性能参数上已逐步对标外资品牌，部分关键技术实现行业领先，市场竞争 力显著增强，国产替代进程明显提速。 上述医疗器械注册证的取得主要包括内镜主机（含图像处理器和光源）、内 镜镜体（含上消化道电子内窥镜和下消化道电子内窥镜）及内镜周边设备，用于 早癌诊断和治疗。其中，借助高性能硬平台电子光学系统，可在医生经验的基础 上提高诊断的敏感性和特异性，以保障诊断的正确率，在图像、操控性、智能化 等方面的创新与升级，为内镜诊疗打造了高画质与高效率的平台。 杭州安杰思医学科技股份有限公司 关于获得医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公 ...

北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2025年第三次临时股东会的 法律意见 熏恒律师事务所 DeHeng Law Offices 电话:0571-86508080 传真:0571-87357755 邮编:310020 杭州市上城区新业路 200 号华峰国际商务大厦 10、11 楼 北京德恒(杭州)律师事务所 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》等现行有效的法律、法规和规范性文件以及《杭州安杰思医学科技股份有限 公司章程》(以下简称"《公司章程》")而出具。 为出具本法律意见,本所律师审查了本次股东会的有关文件和材料。本所律 师得到公司如下保证:其已提供了本所律师认为作为出具本法律意见所必需的材 料,所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准确、完 整的要求,有关副本、复印件等材料与原始材料一致。 关于杭州安杰思医学科技股份有限公司 2025 年第三次临时股东会的法律意见 北京德恒(杭州)律师事务所 关于杭州安杰思医学科技股份有限公司 2025年第三次临时股东 ...

（一） 股东会召开的时间：2025 年 12 月 24 日 （二） 股东会召开的地点：杭州市临平区兴中路 389 号三楼 302 会议室 证券代码：688581 证券简称：安杰思 公告编号：2025-067 杭州安杰思医学科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 74 | | --- | --- | | 普通股股东人数 | 74 | | 2、出席会议的股东所持有的表决权数量 | 51,795,021 | | 普通股股东所持有表决权数量 | 51,795,021 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 63.8644 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 63.8644 | 注：截至本次股东会股权 ...

Core Viewpoint - Anjias (688581.SH) announced that its subsidiary Hang'an Medical Technology (Hangzhou) Co., Ltd. has received medical device registration certificates from the Zhejiang Provincial Drug Administration for several endoscopic products, enhancing its product line in the endoscopy field [1] Group 1: Product Registration - The registered products include electronic endoscope image processors, upper gastrointestinal electronic endoscopes, and lower gastrointestinal electronic endoscopes [1] - The acquisition of these medical device registration certificates enriches the company's product offerings in the endoscopy diagnosis and treatment sector [1] Group 2: Market Competitiveness - The new product registrations are expected to meet diverse clinical needs, thereby improving the company's overall market competitiveness [1] - This development is anticipated to have a positive impact on the company's sustainable growth [1]